Federal Register #FDA-2026-N-7232

FDA Strategy for CMC Readiness in Accelerated Drug and Biologic Development

This opportunity is an informational notice from the Food and Drug Administration (FDA) regarding a new strategy for chemistry, manufacturing, and controls (CMC) readiness: - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Purpose: - FDA is publishing a strategy to support CMC readiness for drugs and biologics with accelerated clinical development timelines - Focuses on products regulated by CDER and CBER intended for serious diseases or conditions with unmet medical needs - Key Details: - No procurement of products or services is requested - No OEMs, vendors, or part numbers are mentioned - The notice provides guidance and regulatory flexibilities, especially for cell and gene therapies - Aims to enhance regulatory processes and patient access to innovative therapies - Notable Requirements: - This is a policy and guidance announcement, not a solicitation for goods or services - References lessons learned and public input to inform future actions - No purchase quantities, contract values, or period of performance are specified

Description

The Food and Drug Administration (FDA) announces the publication of its Strategy Document outlining actions taken and plans for fiscal years 2026-2027 to facilitate chemistry, manufacturing, and controls (CMC) readiness for products with accelerated clinical development timelines. This strategy supports sponsors of CDER- and CBER-regulated drugs and biologics intended to address serious diseases or conditions with unmet medical needs. The document is based on lessons learned from FDA's experience and public input, aiming to enhance regulatory processes and timely patient access to innovative therapies.

View original listing